Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 642

1.

Structural Analysis of The OXA-48 Carbapenemase Bound to A "Poor" Carbapenem Substrate, Doripenem.

Papp-Wallace KM, Kumar V, Zeiser ET, Becka SA, van den Akker F.

Antibiotics (Basel). 2019 Sep 11;8(3). pii: E145. doi: 10.3390/antibiotics8030145.

2.

Antimicrobial susceptibility surveillance of obligate anaerobic bacteria in the Kinki area.

Shimura S, Watari H, Komatsu M, Kuchibiro T, Fukuda S, Nishio H, Kita M, Kida K, Oohama M, Toda H, Nishio M, Nishi I, Kimura K, Sawa K, Fukuda N, Kofuku T, Nakai I, Niki M, Ono T, Nakamura T, Wada Y.

J Infect Chemother. 2019 Aug 17. pii: S1341-321X(19)30229-6. doi: 10.1016/j.jiac.2019.07.018. [Epub ahead of print]

PMID:
31427200
3.

Overview and Insights into Carbapenem Allergy.

Lee Y, Bradley N.

Pharmacy (Basel). 2019 Aug 8;7(3). pii: E110. doi: 10.3390/pharmacy7030110. Review.

4.

Structural Insights into the Mechanism of Carbapenemase Activity of the OXA-48 β-Lactamase.

Smith CA, Stewart NK, Toth M, Vakulenko SB.

Antimicrob Agents Chemother. 2019 Jul 29. pii: AAC.01202-19. doi: 10.1128/AAC.01202-19. [Epub ahead of print]

PMID:
31358584
5.

Continuous high-dose infusion of doripenem in a pneumonia patient infected by carbapenem-resistant Pseudomonas aeruginosa: a case report.

Oda K, Kamohara H, Katanoda T, Hashiguchi Y, Iwamura K, Nosaka K, Jono H, Saito H.

J Pharm Health Care Sci. 2019 Jul 8;5:15. doi: 10.1186/s40780-019-0144-4. eCollection 2019.

6.

Carbapenemase-producing bacteria in food-producing animals, wildlife and environment: A challenge for human health.

Bonardi S, Pitino R.

Ital J Food Saf. 2019 Jun 20;8(2):7956. doi: 10.4081/ijfs.2019.7956. eCollection 2019 May 23.

7.

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017).

Sader HS, Castanheira M, Streit JM, Flamm RK.

Diagn Microbiol Infect Dis. 2019 Jun 11:114850. doi: 10.1016/j.diagmicrobio.2019.06.002. [Epub ahead of print]

PMID:
31296360
8.

The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections-A Systemic Review and Meta-Analysis of Randomized Controlled Trials.

Lai CC, Cheng IL, Chen YH, Tang HJ.

J Clin Med. 2019 Jul 2;8(7). pii: E958. doi: 10.3390/jcm8070958. Review.

9.

Antimicrobial Resistance, Virulence Factors, and Pathotypes of Escherichia coli Isolated from Drinking Water Sources in Jordan.

Swedan S, Abu Alrub H.

Pathogens. 2019 Jun 25;8(2). pii: E86. doi: 10.3390/pathogens8020086.

10.

Phenotypic and Genotypic Characterization of Carbapenem-Resistant Gram-Negative Bacilli Pathogens from Hospitals in Ghana.

Codjoe FS, Donkor ES, Smith TJ, Miller K.

Microb Drug Resist. 2019 Jun 25. doi: 10.1089/mdr.2018.0278. [Epub ahead of print]

PMID:
31237486
11.

Characterization of Phenotypic and Genotypic Diversity of Stenotrophomonas maltophilia Strains Isolated From Selected Hospitals in Iran.

Bostanghadiri N, Ghalavand Z, Fallah F, Yadegar A, Ardebili A, Tarashi S, Pournajaf A, Mardaneh J, Shams S, Hashemi A.

Front Microbiol. 2019 May 29;10:1191. doi: 10.3389/fmicb.2019.01191. eCollection 2019.

12.

Eravacycline (Xerava)--an IV tetracycline for complicated intra-abdominal infections.

[No authors listed]

Med Lett Drugs Ther. 2019 Apr 22;61(1570):61-63. No abstract available.

PMID:
31169809
13.

Synergistic effect of doripenem in combination with cefoxitin and tetracycline in inhibiting NDM-1 producing bacteria.

Maryam L, Khalid S, Ali A, Khan AU.

Future Microbiol. 2019 May;14:671-689. doi: 10.2217/fmb-2019-0032. Epub 2019 Jun 4.

PMID:
31161792
14.

Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia.

Liu WD, Shih MC, Chuang YC, Wang JT, Sheng WH.

J Microbiol Immunol Infect. 2019 May 14. pii: S1684-1182(19)30045-3. doi: 10.1016/j.jmii.2019.04.008. [Epub ahead of print]

15.

Association of Adverse Drug Events with Broad-spectrum Antibiotic Use in Hospitalized Patients: A Single-center Study.

Hagiya H, Kokado R, Ueda A, Okuno H, Morii D, Hamaguchi S, Yamamoto N, Yoshida H, Tomono K.

Intern Med. 2019 Sep 15;58(18):2621-2625. doi: 10.2169/internalmedicine.2603-18. Epub 2019 May 22.

16.

Doripenem dosing regimens in Asian critically ill patients with continuous renal replacement therapy.

Chaijamorn W, Puchsaka P, Pattharachayakul S, Charoensareerat T, Srisawat N, Boonpeng A, Pummangura C.

J Crit Care. 2019 Aug;52:233-236. doi: 10.1016/j.jcrc.2019.04.030. Epub 2019 Apr 29. No abstract available.

PMID:
31108327
17.

Effect of pharmacokinetic model misspecification on antibiotic probability of target attainment predicted by Monte Carlo simulation
.

Kim SW, Kim DJ, Zang DY, Lee DH.

Int J Clin Pharmacol Ther. 2019 Jul;57(7):362-374. doi: 10.5414/CP203446.

PMID:
31094317
18.

lptG contributes to changes in membrane permeability and the emergence of multidrug hypersusceptibility in a cystic fibrosis isolate of Pseudomonas aeruginosa.

Harrison LB, Fowler RC, Abdalhamid B, Selmecki A, Hanson ND.

Microbiologyopen. 2019 Apr 12:e844. doi: 10.1002/mbo3.844. [Epub ahead of print]

19.

Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.

Matsuo Y, Ishibashi T, Matsumoto S, Katsube T, Wajima T.

J Pharm Sci. 2019 Sep;108(9):3099-3105. doi: 10.1016/j.xphs.2019.04.002. Epub 2019 Apr 8.

PMID:
30974120
20.

Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital.

Chotiprasitsakul D, Srichatrapimuk S, Kirdlarp S, Pyden AD, Santanirand P.

Infect Drug Resist. 2019 Feb 20;12:461-468. doi: 10.2147/IDR.S192540. eCollection 2019.

Supplemental Content

Loading ...
Support Center